Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazax in Seasonal Grass Pollen Induced Rhinoconjunctivitis (GT-08)
NCT00227279Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Oct 2004
- Primary completion
- Sep 2009
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing Grazax with Placebo (2 arms). Primary endpoints: Rhinoconjunctivitis Symptom Score and Rescue Medication Score. Started Oct 2004; status: completed.
02
Drugs
grass-pollen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00227279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227279.